Jefferies initiated coverage of BioAge Labs (BIOA) with a Buy rating and $42 price target BioAge is a clinical stage biotech focusing on metabolic diseases, the analyst tells investors in a research note. The firm says the company’s lead drug Azelaprag has a differentiated mechanism of action as exercise mimetic for obesity.
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
BioAge Labs initiated with a Buy at Jefferies
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App